Merck & Co. (NYSE:MRK) has entered into a research collaboration with Isomorphic Labs to identify and develop potential small-molecule cancer treatments using artificial intelligence, combining the pharmaceutical group’s drug discovery expertise with advanced computational modelling technology.
The agreement will focus on discovering drug candidates directed at an undisclosed oncology target. The companies intend to use AI-driven molecular design and proprietary research data to accelerate the identification of compounds with potential therapeutic applications.
Under the partnership, Isomorphic Labs will apply its proprietary artificial intelligence drug design engine, IsoDDE, to generate computational predictions and molecular designs. Merck will contribute proprietary datasets and its expertise in pharmaceutical research and development.
The collaboration represents another application of artificial intelligence in drug discovery, where computational technologies are being explored to improve the efficiency of identifying and evaluating potential treatments.
Isomorphic Labs will use its IsoDDE technology to support the discovery of small-molecule drug candidates targeting the selected oncology programme.
The platform will perform computational predictions and produce molecular designs intended to guide the research process.
Merck will provide proprietary datasets to support the computational work, allowing the collaboration to combine experimental information with advanced modelling capabilities.
The companies aim to use these complementary resources to identify promising molecular structures and support the development of potential cancer treatments.
Although the specific oncology target has not been disclosed, the agreement establishes a division of responsibilities between the two organisations.
Isomorphic Labs will concentrate on computational drug discovery and molecular design, while Merck will oversee the subsequent development and commercialisation stages.
Under the terms of the agreement, Merck will assume responsibility for preclinical and clinical development of any drug candidates emerging from the collaboration.
The pharmaceutical company will also manage manufacturing and commercialisation activities for any resulting products.
This structure allows Isomorphic Labs to focus on its artificial intelligence technology and computational research capabilities while drawing on Merck’s experience in advancing pharmaceutical products through development and regulatory processes.
Any potential drug candidates would still need to undergo the necessary preclinical studies, clinical trials and regulatory evaluations before they could become commercially available treatments.
The companies have not disclosed a development timetable or identified specific compounds associated with the programme.
The research partnership includes an upfront payment from Merck to Isomorphic Labs, although the amount has not been disclosed.
Isomorphic Labs will also be eligible to receive additional payments linked to research, development, regulatory and commercial milestones.
The agreement provides for tiered royalties based on net sales of any products developed through the collaboration.
In addition, Isomorphic Labs has secured an option to co-fund development activities in exchange for higher royalty rates.
This provision would allow the company to increase its financial participation in the development of successful candidates while potentially receiving a larger share of future product sales.
The financial terms of the agreement were not fully disclosed, including the value of the upfront payment, potential milestone payments and applicable royalty percentages.
George Addona, senior vice president and head of discovery, preclinical development and translational medicine at Merck Research Laboratories, highlighted the complementary capabilities of the two companies.
“By bringing together Merck’s extensive proprietary data and drug discovery expertise with Isomorphic Labs’ advanced modelling and computational capabilities, we aim to find new approaches to designing and identifying better drug candidates more quickly,” Addona said.
The comments reflect the companies’ intention to combine established pharmaceutical research methods with artificial intelligence-based molecular modelling.
The approach is intended to support more efficient drug candidate identification, although its effectiveness in producing clinically successful treatments remains to be established.
The collaboration also reflects Merck’s interest in applying computational technologies to its oncology research activities.
Sarah Skerratt, chief research officer at Isomorphic Labs, said the partnership would provide an opportunity to apply the company’s drug design technology to a demanding research programme.
Skerratt said the collaboration aims to use IsoDDE to “achieve meaningful advances in drug discovery” against a target she characterised as particularly challenging.
The research effort will draw on Isomorphic Labs’ computational capabilities alongside Merck’s proprietary datasets and pharmaceutical development experience.
The companies expect the combination of these resources to support the identification of potential drug candidates, although no specific development outcomes have been announced.
Founded in 2021, Isomorphic Labs specialises in applying artificial intelligence to pharmaceutical research and molecular design.
The company is headquartered in London and maintains additional offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
Its research activities focus on using computational technologies to support the discovery and design of potential therapeutic compounds.
The agreement with Merck provides an opportunity to apply the company’s IsoDDE platform to an oncology programme supported by a major pharmaceutical developer.
For Merck, the collaboration provides access to specialised AI-driven drug design capabilities that can complement its existing research infrastructure.
The partnership between Merck and Isomorphic Labs establishes a new research programme combining artificial intelligence, proprietary pharmaceutical data and established drug development capabilities.
Isomorphic Labs will lead computational predictions and molecular design, while Merck will be responsible for preclinical and clinical development, manufacturing and commercialisation of any resulting treatments.
The financial structure includes an undisclosed upfront payment, potential milestone payments, tiered royalties and an option for Isomorphic Labs to co-fund development in exchange for higher royalty rates.
Although the companies have not identified the oncology target or disclosed a development timeline, the agreement illustrates the growing role of computational modelling in pharmaceutical research.
The programme remains at the drug discovery stage, and any future commercial opportunity will depend on the identification of suitable candidates and their successful progression through clinical development and regulatory approval.
Merck stock price
| 53 min | |
| 2 hours | |
| Nov-18 | |
| Nov-18 | |
| Nov-18 | |
| Nov-17 | |
| Nov-17 | |
| Nov-16 | |
| Nov-13 | |
| Nov-13 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-12 | |
| Nov-11 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite